Biocon Limited (NSE: BIOCON, BSE: 532523) is a Bengaluru, Karnataka-based company in the Biological Products industry. With a market capitalisation of ₹59,929 Cr, it ranks #179 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 5 in Biological Products. At ₹364.05 (as of 16 Nov 2026), the share price is 18.6% below its 52-week high of ₹447.15 and 14.3% above its 52-week low of ₹318.40. The share price is down 4.3% over one year and down 13.3% over three months.
| Current Price | ₹364.05 |
|---|---|
| Market Cap | ₹59,929 Cr |
| NSE Symbol | BIOCON |
| BSE Code | 532523 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | 131.2 |
| Return on Equity | 1.15% |
| Return on Assets | 1.73% |
| 52-Week Range | ₹318.40 – ₹447.15 |
| 1-Year Price Change | -4.3% |
| 3-Month Price Change | -13.3% |
| Beta (1Y) | 0.01 |
| Dividend Yield | 0.14% |
| Headquarters | Bengaluru, Karnataka |
| Website | www.biocon.com |
| Revenue | ₹4,389 Cr |
|---|---|
| Net Profit | ₹57 Cr |
| Net Margin | 1.3% |
| EPS (Basic) | ₹0.25 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Biocon Limited reported revenue of ₹4,389 Cr in Q2 FY27, up 2.2% from ₹4,296 Cr in Q2 FY26 and up 1.2% from ₹4,336 Cr in Q1 FY27. It posted a net profit of ₹57 Cr for the quarter, against a net profit of ₹133 Cr in Q2 FY26 (down 57.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹3,942 Cr (Q1 FY26) to ₹4,517 Cr (Q4 FY26). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹4,389 Cr | ₹57 Cr | 1.3% |
| Q1 FY27 | ₹4,336 Cr | ₹137 Cr | 3.2% |
| Q4 FY26 | ₹4,517 Cr | ₹199 Cr | 4.4% |
| Q3 FY26 | ₹4,173 Cr | −₹52 Cr | −1.2% |
| Q2 FY26 | ₹4,296 Cr | ₹133 Cr | 3.1% |
| Q1 FY26 | ₹3,942 Cr | ₹89 Cr | 2.3% |
| Q4 FY25 | ₹4,417 Cr | ₹459 Cr | 10.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 44.68% of Biocon Limited's shares as of Sept 2026, against 54.45% in Dec 2025 (−9.77 percentage points). Delivery averaged 44.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals
1. Generics-This segment develops a portfolio of small molecule generics. 2. Biosimilars-This segment focuses on developing various biosimilars. 3. Research Services-This segment provides integrated drug discovery and development services in chemistry, biology, in vivo and in vitro pharmacology, toxicology, custom synthesis, process research and development, cGMP manufacturing, formulation, analytical development, and clinical development. 4. Inter-Segment Revenue-0
1. Biosimilars-61.6% 2. Generics-18.7%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹59,929 Cr | 131.2 | 1.15% | ₹4,389 Cr | -4.3% |
| Hester Biosciences Ltd | ₹1,985 Cr | 35.7 | 16.55% | ₹98 Cr | +46.0% |
| Zenotech Laboratories Ltd | ₹241 Cr | n/m | -1.12% | — | -22.5% |
| Transgene Biotek Ltd. | ₹19 Cr | n/m | -17.96% | ₹0 Cr | -22.1% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | n/m | -9.12% | — | -0.4% |
Listed by market capitalisation. Ratios are shown for context only.
Biocon Limited is trading at ₹364.05, with a market capitalisation of ₹59,929 Cr.
Biocon Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Biocon Limited has a P/E of 131.2 and a return on equity of 1.15%.
Biocon Limited is listed on the NSE under the symbol BIOCON and on the BSE under the scrip code 532523.
Biocon Limited's share price is down 4.3% over one year and down 13.3% over three months. Its 52-week range is ₹318.40 to ₹447.15.
In Q2 FY27, Biocon Limited reported revenue of ₹4,389 Cr and net profit of ₹57 Cr, with basic EPS of ₹0.25 (consolidated, parsed from the company's exchange filing).
Biocon Limited reported revenue of ₹4,389 Cr in Q2 FY27, up 2.2% from ₹4,296 Cr in Q2 FY26 and up 1.2% from ₹4,336 Cr in Q1 FY27.
Promoters held 44.68% of Biocon Limited's shares as of Sept 2026, against 54.45% in Dec 2025 (−9.77 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.